Pre-clinical Exploratory Evaluation of Mab806-derived Immunotoxin in Targeting Solid Tumors with High Potency and Selectivity Towards EGFR<sub>vIII</sub>
نویسندگان
چکیده
Background and objectivesThe overexpression mutation of EGFRs are associated with various types human cancers. Epidermal growth factor receptor variant III (EGFRvIII) is one the most notable EGFR mutations, exclusively present in cancer cells, making it a potential therapeutic target. The study aims to determine whether recombinant immunotoxin 86 (rIT86) can effectively kill EGFRvIII-expressing while maintaining adequate levels tolerance.
منابع مشابه
Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.
The TNF-like weak inducer of apoptosis (TWEAK; TNFSF12) receptor Fn14 (TNFRSF12A) is expressed at low levels in normal tissues but frequently highly expressed in a wide range of tumor types such as lung, melanoma, and breast, and therefore it is a potentially unique therapeutic target for these diverse tumor types. We have generated a recombinant protein containing a humanized, dimeric single-c...
متن کاملRecombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.
Immunotoxins are a group of protein-based therapeutics, basically comprising two functional moieties: one is the antibody or antibody Fv fragment that allows the immunotoxin to bind specifically to target cells; another is the plant or bacterial toxin that kills the cells upon internalization. Immunotoxins have several unique features which are superior to conventional chemotherapeutics, includ...
متن کاملAnticancer metallohelices: nanomolar potency and high selectivity.
A range of new helicate-like architectures have been prepared via highly diastereoselective self-assembly using readily accessible starting materials. Six pairs of enantiomers [Fe2L3]Cl4·nH2O (L = various bidentate ditopic ligands NN-NN) show very good water solubility and stability. Their activity against a range of cancer cell lines in vitro is structure-dependent and gives IC50 values as low...
متن کاملEGFR targeting of solid tumors.
BACKGROUND Recent clinical trials suggest that epidermal growth factor receptor (EGFR)-targeted agents could benefit many patients with cancer. METHODS We review the current status of several EGFR-targeted therapies in cancer patients and address the efficacy of theses drugs as monotherapy or in combination with other drugs and/or treatments. RESULTS Cetuximab is the most widely studied ant...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of exploratory research in pharmacology
سال: 2022
ISSN: ['2572-5505']
DOI: https://doi.org/10.14218/jerp.2022.00005